Roche in Oncology Media Fair

ข่าวต่างประเทศ Wednesday May 31, 2006 10:55 —Asianet Press Release

BASEL--31 May--PRNewswire-Asianet/InfoQuest Developing Oncology Solutions Friday, 2 June 2006 (9:00 a.m. - 1:00 p.m.) Atlanta Marriott Marquis Hotel (For Non-U.S. Journalists Only) WHAT: Exclusive preview of Roche worldwide oncology franchise's ground-breaking data. Don't miss this unique opportunity to hear first-hand about the latest targeted and innovative therapies: * Avastin: first anti-angiogenic agent for breast, colorectal and non-small cell lung cancer * Bondronat: only single nitrogen bisphosphonate for metastatic bone disease * Herceptin: first biologically engineered, monoclonal antibody to treat breast cancer * Mabthera: the world's first monoclonal antibody therapy for the treatment of non-Hodgkin's lymphoma * Tarceva: only EGFR-inhibitor with a survival benefit in lung cancer * Xeloda: unsurpassed patient convenience with an oral chemotherapy regimen for breast and colorectal cancers WHY: -- Preview the latest cancer data from one of the world's premiere oncology portfolios -- Access to leading oncology experts and Roche senior executives in a one-to-one interview format, immediately following the Media Fair WHERE: Atlanta Marriott Marquis Hotel Marquis Ballroom, Salon 3 (Media Fair Exhibit) & Consulate Room (Key Data Presentations) 265 Peachtree Avenue; Atlanta, Georgia USA WHEN: Friday, 2 June 2006 (9:00 a.m. to 1:00 p.m.) RSVP: To register for this event and to arrange one-to-one interviews please contact Mitti Bose, Shire Health International via phone ,at +1-212-625-7140, mobile +1-917-804-9084 or via e-mail at [email protected] We suggest you register prior to June 2 to secure you're spot at the briefing, however on-site registration will be available with a press badge/identification. SOURCE: Roche --Distributed by AsiaNet ( www.asianetnews.net )--

แท็ก Breast cancer   Lung cancer   engineer   access   mobile   nation  

เว็บไซต์นี้มีการใช้งานคุกกี้ ศึกษารายละเอียดเพิ่มเติมได้ที่ นโยบายความเป็นส่วนตัว และ ข้อตกลงการใช้บริการ รับทราบ